ANTI-CD25 A OPTIMISATION FC POUR EPUISEMENT DE CELLULES SPECIFIQUES TUMORALES

• 收藏
• 分享

专利权人:

TUSK THERAPEUTICS LTD;CANCER RESEARCH TECHNOLOGY LIMITED

发明人:

GOUBIER, ANNE,MERCHIERS, PASCAL,SALIMU, JOSEPHINE,GOYENECHEA, BEATRIZ,MOULDER, KEVIN,QUEZADA, SERGIO,PEGGS, KARL,VARGAS, FRED ARCE,SOLOMON, ISABELLE

申请号：

CA3056506

公开号：

CA3056506A1

申请日:

2018.03.13

申请国别(地区):

CA

年份:

2018

代理人:

摘要：

The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2 - CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/